Aardvark Therapeutics, Inc.
AARD
$8.49
-$0.50-5.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 75.64% | 127.21% | 84.74% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 235.02% | 295.75% | 207.28% | -- | -- |
| Operating Income | -235.02% | -295.75% | -207.28% | -- | -- |
| Income Before Tax | -211.10% | -252.81% | -185.63% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -211.10% | -252.81% | -185.63% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -211.10% | -252.81% | -185.63% | -- | -- |
| EBIT | -235.02% | -295.75% | -207.28% | -- | -- |
| EBITDA | -395.54% | -1,332.29% | -- | -- | -- |
| EPS Basic | -54.17% | -166.79% | -182.04% | -- | -- |
| Normalized Basic EPS | -60.20% | -201.62% | -235.68% | -- | -- |
| EPS Diluted | -54.17% | -166.79% | -182.04% | -- | -- |
| Normalized Diluted EPS | -60.20% | -201.62% | -235.68% | -- | -- |
| Average Basic Shares Outstanding | 170.65% | 59.04% | 0.89% | -- | -- |
| Average Diluted Shares Outstanding | 170.65% | 59.04% | 0.89% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |